Halozyme Therapeutics HALO

HealthcareMarket cap $7B2 connections

Halozyme's ENHANZE drug delivery technology - using an enzyme to create temporary space under the skin - converts IV infusions into quick subcutaneous injections. Roche, Pfizer, Janssen, and Argenx pay Halozyme royalties to use ENHANZE for their drugs. A 4-hour IV infusion becomes a 5-minute injection, transforming patient experience.

Explore Halozyme Therapeutics on the interactive map Relationship timeline Find a path to another company

Partners 2

Strategic partnerships, joint products and alliances

AbbVieHealthcare · $320BAbbVie ENHANZE collaboration with Halozyme
PfizerHealthcare · $160BRoche uses Halozyme ENHANZE for subcutaneous drugs

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Halozyme Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=HALO" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Halozyme Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.